The number of molecularly stratified treatment options available to patients with colorectal
cancer (CRC) is increasing, with a parallel rise in the use of biomarkers to guide …

In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. One of the
fundamental processes driving the initiation and progression of CRC is the accumulation of …

Colorectal cancer (CRC) is a leading cause of cancer death worldwide. It includes different
subtypes that differ in their clinical and prognostic features. In the past decade, in addition to …

Sporadic colorectal cancer (CRC) is a somatic genetic disease in which pathogenesis is
influenced by the local colonic environment and the patient's genetic background …

Roughly 50% of cancer cases occur in people aged 65 years or older. Older people are
often diagnosed at a later stage and might receive less (intensive) treatment, which might …

This review gives an account of recent advances in our knowledge of the molecular
mechanisms in colorectal cancer. Genetic changes in the germ line, combined with somatic …

Colorectal cancer (CRC) is a leading cause of cancer deaths worldwide. It results from an
accumulation of genetic and epigenetic changes in colon epithelial cells, which transforms …

Approximately 30% of colorectal carcinomas develop via a serrated neoplasia pathway,
named for the pattern of crypts in the precursor polyps. Molecular abnormalities consistently …

The “serrated neoplastic pathway” describes the progression of serrated polyps, including
sessile serrated adenomas and traditional serrated adenomas, to colorectal cancer. The …